Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q2 FY2026 Earnings Presentation
33 slides from Gufic Biosciences's earnings presentation, Nov 14, 2025
Slide 1: Stock exchange filing cover letter
308/LG/SE/NOV/2025/GBSL November 14, 2025 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presen
Slide 2: Delivering Care & Cure: Investor Presentation for Q2FY2025
Delivering Care & Cure Investor Presentation For Q2FY2025
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions. This prese ntation does not constitute or form part of any offer or invitation
Slide 4: Q2 FY26 Business & Financial Highlights
Q2 FY26 Business & Financial Highlights
Slide 5: Indore Facility update: Progress on track as planned
Indore Facility update: Progress on track as planned We have built one of the most advanced lyophilized Timeline of our phased approach injectable facilities, commenced production in Milestone Target Status & Commentary October 2024 Installation & Operational ✅ Completed – facility meets WHO GMP, EU
Slide 6: Hospital Injectable Platform
I. Hospital Injectable Platform. Therapy Focus: Anti-Microbials, Immunology & Cardiac Critical Care A. Critical Care Cluster B. Sparsh Executing a hospital-focused strategy to scale coverage, deepen retention, and Building a hospital-centric platform in contrast media, nutrition, and cardiac grow sh
Slide 7: Complex injectable pipeline for the hospital platform
Complex injectable pipeline for the hospital platform Drug Class Unique Advantages Complexity in Manufacturing Domestic Business Breakup Novel β-lactam/β- Targets multi-drug resistant Gram-negative Complex formulation with dual agents requires precise lactamase Inhibitor bacteria; highly effective f
Slide 8: Women's Health Platform
II. Women’s Health Platform. Therapy Focus: Assisted Reproductive Technology(IVF), Immunology & Ortho-gynae A. Ferticare Cluster B. Zenova Building scientific leadership in advanced fertility injectables and reproductive Scaling a stable, specialty-focused women’s health & ortho platform. immunology
Slide 9: Botulinum Toxin Platform
III. Botulinum Toxin Platform. Therapy Focus: Aesthetics & Neurology A. Aesthaderm B. Neurocare Evolving from toxin leadership into a full-stack aesthetics ecosystem. Scaling the Therapeutic Toxin Franchise Through Injector Creation & Category Expansion 1. Accelerating Multi-Category Portfolio Expan
Slide 10: Nutra, Ayurveda & Others
IV. Nutra, Ayurveda & Others. Therapy Focus: Chronic Musculoskeletal Pain & Gastro Healthcare Creating a science-backed, modern Ayurvedic & musculoskeletal care franchise. 1. Strengthening Scientific Foundations in Ayurveda ➢ Online and offline educational engagements building credibility and next-
Slide 11: CMO & International Business
V. CMO & International Business: Converting complex injectables expertise into a global sales and licensing engine. RA Status--> Key Products with Stringent Countries-Ready Dossiers Strategic Roadmap (3–5 Years) Regulated Market Current Market Size ➢ Market Share Goal: Capture 5–10% in identified ge
Slide 12: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In -house Critical Developing SVX-3001 (humanized anti-CD40 agonist antibody) co-administered intratumorally with IL-2 to API Manufacturing: Our foray into peptides research amplify anti-tumour immune response w
Slide 13: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 14: Profit & Loss Statement
Profit & Loss Statement Particulars Q2 FY26 Q1 FY26 Q2 FY25 H1 FY26 H1 FY25 (in Rs. Crore) Total Revenue 230.4 226.9 204.2 457.3 407 EBITDA 37.9 33.2 38.7 71.1 75.8 EBITDA Margin % 16.45% 14.63% 18.95% 15.55% 18.62% Profit before Tax 20.5 16.3 29.3 36.8 57.4 PBT Margins % 8.90% 7.18% 14.35% 8.05% 14
Slide 15: Company Overview
Company Overview
Slide 16: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 17: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 18: New Manufacturing Infrastructure
New Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Commercial Production Achieved Facility Carbapenems (Lyophilized / Dry Capability to cater to regulated Powder Inj / Oral Solids / Dual markets such as
Slide 19: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 20: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 21: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 22: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 23: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 24: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 25: Extensive Sales, Distribution & IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 26: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 27: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 28: Historical Financials
Historical Financials
Slide 29: Historical Financials
Historical Financials Particulars (Rs. Crs.) H1 FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Total Revenue 457.3 823.4 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 71.1 140 149.5 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 15.55% 17.00% 18.48% 19.79% 19.31% 17.85% 15.05% 15.77% Profit before Tax 36.8 94.4 1
Slide 30: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Sep-25 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 10 10 9.7 9.7 9.7 9.7 7.8 Other Equity 618.5 591.3 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 628.5 601.3 532.5 347.8 269.1 173.4 129.3
Slide 31: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Sep-25 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 467.6 475.2 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 6.3 6.3 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 24.0 21.8 307.1 169.6 4
Slide 32: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) H1 FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 36.8 94.4 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 33.5 43.8 34.1 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before wor
Slide 33: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000